Irinotecan Hydrochloride
FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adenocarcinoma
- Cancer
- Carcinoma
- Malignant Pancreatic Neoplasm
- Neoplasm
- Pancreatic carcinoma
- Pancreatic neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Topoisomerase 1 (top1) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
NCT00033657 · start 2002-08-15
Registered record
- Registry ID
- NCT00033657
- Conditions
- Esophageal Cancer; Gastric Cancer
- Interventions
- cisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08-15
- Completion
- 2009-10
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEsophageal Cancer; Gastric CancerInterventioncisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery +1 morePhasePhase 2Registry statusCompletedImatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00248482 · start 2002-02
Registered record
- Registry ID
- NCT00248482
- Conditions
- Lung Cancer
- Interventions
- Cisplatin; Gleevec™; irinotecan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2008-01
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung CancerInterventionCisplatin; Gleevec™; irinotecanPhasePhase 2Registry statusCompletedZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00030524 · start 2002-01
Registered record
- Registry ID
- NCT00030524
- Conditions
- Colorectal Cancer
- Interventions
- gefitinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-01
- Completion
- 2003-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventiongefitinibPhasePhase 2Registry statusCompletedZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
NCT00026364 · start 2001-11
Registered record
- Registry ID
- NCT00026364
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2001-11
- Completion
- Not recorded
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionfluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calciumPhasePhase 1Registry statusCompletedCetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
NCT00020917 · start 2001-02
Registered record
- Registry ID
- NCT00020917
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-02
- Completion
- 2004-02
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventioncetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calciumPhasePhase 2Registry statusCompleted